BerandaMOLN • SWX
add
Molecular Partners AG
Tutup sebelumnya
CHF 4,89
Rentang hari
CHF 4,89 - CHF 4,99
Rentang tahun
CHF 3,11 - CHF 9,50
Kapitalisasi pasar
200,20 jt CHF
Volume Rata-Rata
20,26 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
SWX
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (CHF) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 681,00 rb | -73,20% |
Biaya operasional | 4,41 jt | -0,38% |
Laba bersih | -16,40 jt | -43,40% |
Margin laba bersih | -2,41 rb | -435,08% |
Penghasilan per saham | -0,49 | — |
EBITDA | -14,00 jt | -8,64% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (CHF) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 143,62 jt | -30,49% |
Total aset | 154,21 jt | -29,30% |
Total liabilitas | 15,43 jt | -29,56% |
Total ekuitas | 138,78 jt | — |
Saham yang beredar | 33,19 jt | — |
Harga terhadap nilai buku | 1,17 | — |
Tingkat pengembalian aset | -22,46% | — |
Tingkat pengembalian modal | -24,30% | — |
Arus Kas
Perubahan kas bersih
| (CHF) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -16,40 jt | -43,40% |
Kas dari operasi | -13,28 jt | -0,68% |
Kas dari investasi | 14,22 jt | -20,00% |
Kas dari pembiayaan | -301,00 rb | -1,01% |
Perubahan kas bersih | 66,00 rb | -98,72% |
Arus kas bebas | -8,09 jt | -4,19% |
Tentang
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Didirikan
2004
Karyawan
162
